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Four successive, rapid serial passages of the nonpathogenic, CCR5-tropic simian–human immunodeficiency virus SHIVSF162 in rhesus
macaques resulted in an increase in acute plasma viremia with each passage and the emergence of a pathogenic isolate SHIVSF162P3 in one of
the passage three transfer animals (macaque T353). To explore the mechanism(s) underlying increased virulence of SHIVSF162 upon in vivo
passage, the evolution of the HIV-1 envelope gene was characterized in plasma and PBMC samples obtained from animals before (week 1)
and after (week 3) the time of virus transfer. We found no evidence in support of adaptive evolution of the HIV gp120 during rapid serial
passage; however, the animals which later received passage virus had more diverse quasispecies. SHIVSF162P3-like gp120 sequences were
first detected in macaque T353 at week 6, after seroconversion. These sequence changes increased in frequency and number at later time
points. The first sequence change conferred neutralization escape but not an increase in viral infectivity that could account for the apparent
increase in replicative capacity of the later passage viruses. Collectively, our data argue against any host-specific adaptation of the HIV-1
envelope gp120 as the basis for the generation of more aggressive SHIV variants during rapid serial transfers in seronegative macaques, and
support the model of quasispecies diversity as a predictor of pathogenesis. Envelope sequence changes accumulate principally in response to
immune pressure exerted by the host, generating viral variants that can persist in the presence of a strong host immune response.
D 2003 Elsevier Inc. All rights reserved.Keywords: Quasispecies diversity; Adaptive evolution; Seronegative macaquesIntroduction
Chimeric simian–human immunodeficiency viruses
(SHIVs) that contain the HIV-1 tat, rev, vpu, and env genes
inserted into the proviral genome of the pathogenic SIV-
mac239 clone have been constructed to test the functions of
HIV-1 gene products in macaque models (Hayami and
Igarashi, 1997; Overbaugh et al., 1997). Infection of mac-
aques by SHIVs with different co-receptor usage has pro-
vided critical insights into the role of tropism in the rate and
localization of CD4+ T-cell depletion, as well as constitut-
ing a valuable model system in the development and
assessment of candidate vaccines directed against the HIV-
1 envelope glycoproteins (Bogers et al., 2000). However,0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: pbalfe@adarc.org (P. Balfe).SHIV constructs do not readily induce disease in macaques
and require in vivo adaptation and often serial in vivo
passage to acquire the ability to replicate to high titers,
deplete CD4+ T cells, and induce simian AIDS (Harouse et
al., 1999; Hofmann-Lehmann et al., 2002; Joag et al., 1996,
1997; Luciw et al., 1999; Reimann et al., 1996; Tan et al.,
1999). However, the molecular mechanism(s) during serial
passage by which SHIV adapts to replicate efficiently in the
new host and cause disease is not well understood.
We previously reported that infection of two rhesus
macaques with the CCR5-tropic clone SHIVSF162, followed
by three sequential blood–bone marrow transfusions into
naive macaques, resulted in significantly enhanced replica-
tion of the virus in later passage animals and the emergence
of pathogenic variants in a passage three infected animal,
T353 (Harouse et al., 1999; Tan et al., 1999). Macaque
T353 suffered from chronic diarrhea and severe weight loss
and was euthanized at 66 weeks post-inoculation. Cell-free
virus recovered from lymph node mononuclear cell cultures
Table 1
Virological and immunological measurements in serial passage animals
Animal Passage Week
of peak
viremia
Peak viral
load (RNA
copies/ml)
Viral load
at 1 yeara
(RNA
copies/ml)
Gp41b p27b
T373 P1 2 1.2  106 < 1500 +  ve
T528 P1 3 2.0  106 < 1500 + F
T635 P2 2 1.6  107 < 1500 + + + +++ +
T660 P2 1 1.3  107 < 1500 + + + +
T353 P3 1 3.3  107 1.5  105 + + + + ++
T833 P3 1 1.6  107 < 1500 + + ++
T378 P4 1 5.9  107 1.1  104 + +  ve
T642 P4 1 2.3  107 < 1500 + + + + ++
a Detection threshold for viral load assay was 1500 copies/ml.
b Detection of antiviral antibodies in week 3 plasma was performed using
the RIBA HIV-1/2 Strip Immunoblot Assay (SIA), where the values +, ++,
+++ and ++++ indicate increasing reactivity, quantified in accordance with
the manufacturer’s instructions (26).
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shown to be pathogenic without a switch or expansion of
co-receptor usage (Harouse et al., 2001). When inoculated
into naive animals by the intravenous or intravaginal route,
this isolate caused a dramatic loss of CD4+ intestinal T cells
followed by a gradual depletion of peripheral CD4 T cells as
the disease progressed.
Adaptation in response to the new immune environment
or to maximize the interaction of the virus with cells of the
new host has been reported during cross-species transmis-
sion of SIV (Gao et al., 1992; Reimann et al., 1994), and is
associated with an acceleration of disease progression (Valli
et al., 1998). The recovery of cell-free pathogenic isolate
SHIVSF162P3 from and the development of simian AIDS in
T353 led us to examine the evolution of the gp120 region
of the envelope gene of the SHIVSF162 inoculum over time
in all eight of the serially passaged animals shortly before
(week 1 post-inoculation) the time of serial transfer (week
2), as well as following seroconversion (week 3) to
investigate the basis of SHIV adaptation in vivo. The
envelope gene was chosen because it has been demonstrat-
ed that antigenic change and escape from immune sur-
veillance of this gene product plays a critical role in HIV
persistence and pathogenesis (Cayabyab et al., 1999;
Chakrabarti et al., 2002; Etemad-Moghadam et al.,
1999, 2000; Harouse et al., 2001; Karlsson et al.,
1998b; Kimata et al., 1999; Overbaugh and Bangham,
2001; Ross and Rodrigo, 2002; Wyatt and Sodroski,
1998). Indeed, we previously reported that the envelope
gp120 glycoprotein of SHIVSF162P3 mediated better infec-
tivity and conferred enhanced neutralization resistance
compared with SHIVSF162 gp120 (Hsu et al., 2003).Results
Increased replicative capacity and pathogenesis of
SHIVSF162 upon in vivo passage
We performed four rapid in vivo passages of SHIVSF162
in eight naive rhesus macaques to generate variants that
were more pathogenic (Harouse et al., 1999; Tan et al.,
1999). We found that with each successive transfer, viral
replication was enhanced, as evinced by a more than 10-fold
increase in peak viremia in the later passaged animals (Table
1). All eight animals seroconverted by 3 weeks post-inoc-
ulation, mounting strong antibody responses to gp41 and
p27 (Table 1). One each of the passage three and four
animals, T353 and T378, showed chronic infection, with
detectable viral set points of 104–105 RNA copies/ml. The
finding that these later passage viruses appeared to replicate
with better efficiency suggests the evolution of variants with
increased replication capacity and hence pathogenicity in
the new host. Indeed, we found that a cell-free virus
recovered from the passage three macaque T353 at 20
weeks postinfection, SHIVSF162P3, was pathogenic, inducinga disease course that is similar to HIV infection (Harouse et
al., 1999, 2001). To determine whether SHIVSF162 had
adapted to grow better in macaque cells during serial
passage in vivo, we assessed changes in HIV-1 envelope
and the emergence of SHIVSF162P3 (P3)-like sequences at
time points pre- (1 week) and post- (3 weeks) viral transfer
in each of the eight passaged animals.
No evidence for animal-specific viral change during rapid
passage of SHIVSF162
At least three sequences were cloned from each animal
on the first week after infection and at a time 2 weeks later
when seroconversion had occurred. From each time point,
at least 4000 bp of data was obtained. Relatively little
change was seen in the dataset of 96 sequences, the
consensus of the sequences differing from the SF162 input
sequence at only one nucleotide (740 C-T, Fig. 1a).
Inspection of the sequences showed very little evidence
for sequence change during the transfer period (Fig. 1b).
Both synonymous and nonsynonymous polymorphism
were seen, and the overall levels of each type of substi-
tution (Dn and Ds) and the ratio among them (Dn/Ds)
calculated for the entire dataset (Fig. 2). However, within
any single sample set, the number of these polymorphisms
(3–15 polymorphic residues in total, of which 1–5 were
synonymous) was too small for a reliable interpretation of
these values (Nei and Gojobori, 1986; Yang and Nielsen,
2000). Apart from the branch linking the sequences
obtained from the serial transfer experiment to the sequen-
ces from the P3 isolate (0.00579 F 0.00234) and the
branch distinguishing the P3–7 sequence from the other
P3 sequences (0.00677 F 0.00252), none of the branches
inferred by the maximum likelihood analysis was signifi-
cantly greater than zero length (Fig. 2a). That is, all the
sequences obtained from the serial transfer experiment and
the SF162 inoculum sequence formed a single clade
distinct from the P3 sequence set.
Fig. 1. (a) Consensus of 96 clones sequenced. (b) Positions of polymorphic residues.
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Fig. 1 (continued ).
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Fig. 2. (a) Sequence changes in animals during serial transfer. (b) Sequence changes in animal T353 over time.
P. Balfe et al. / Virology 318 (2004) 267–279 271
Fig. 2 (continued ).
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(HKY85 model, 1000 resamplings) confirmed these results,
only the branches separating the P3 sequences from the
main dataset, and distinguishing the P3–7 clone from the
rest of the P3 sequences, gave significant bootstrap values
(both 100%). To assess whether sampling error is responsi-
ble for the relatively few changes seen in gp120 during
serial transfers, subsets of the sequence data were obtained
by removing sequences at random and the bootstrap anal-
yses repeated. Neither of these subsets showed any change
in the average distances obtained, nor were any new
associations suggested. These analyses therefore suggest
that no adaptive changes occurred in the envelope gp120
during the transfer experiment.
Increased diversity, but no adaptation of envelope gp120
sequence upon rapid passage of SHIVSF162
Inspection of the alignment (Fig. 1b) suggested a trend of
increasing polymorphism in samples obtained from the late
passaged animals. We made the simplest possible compar-
ison among the sequences by counting the numbers of
differences among them (Hamming distance). We found
that in the early samples, both the average number of
differences among clones and the maximum between any
pair were generally smaller than in later samples (Fig. 3).
We assessed whether the higher Hamming distance for the
T353 sample (6.58, range: 0–14) was because of the larger
number of clones sequenced by randomly resampling five
clones from the T353 sequence set 1000 times. The averageFig. 3.Hamming distance for these subsets of data was 6.4 and the
mean range 0.8–10.3, leading us to conclude that although
the larger number of samples may have had an effect on the
range, the average pairwise difference obtained among
sequences from T353 was not biased by the larger number
of samples sequenced. Thus, the trend was for the later
passaged animals to have more differences among their
sequences.
SHIVSF162P3(P3)-like sequence motifs accumulate over time
in T353
The original SHIVSF162 inoculum differed from the
consensus of the P3 isolate at 13 amino acid encoding
positions and one synonymous site (nucleotide 507, Fig.
1a). We termed these codons the ‘signature’ of the P3
variant. The original mixed blood–bone marrow inoculum,
which was used to infect T353 and T833, was available for
study, together with five PBMC samples (weeks 1, 6, 12,
16, 20 posttransfusion) and a plasma sample (week 3
posttransfusion) obtained from T353 during the period
before or concurrent with the derivation of the P3 isolate
(20 weeks posttransfusion). Clones derived from these
samples were sequenced and their relationships to the P3
isolate assessed (Fig. 2b). In contrast to the samples from
the serial transfer experiment, the phylogeny linking the
T353 sequences to those obtained from the P3 isolate
showed several sequences which were intermediate between
the SF162 and P3 sequences, suggesting that all of the
evolution of the virus from SHIVSF162 toward the P3 isolate
Table 2
Frequency of signature amino acids in the samples studied
Amino acid number
(nucleotide)a
134
(304)
140
(322-4)
148
(346)
158
(378)
164
(394)
190
(474)
238
(617)
279
(740)
306
(820)
311
(836)
351
(956)
450
(1253)
452
(1258)
Transfer samples
(33)b
Kc K32/T1 D K R K T V15/A18 T R32/K1 G K32/R1 I
Animal T353
Inoculum (11) K K D K R K T V7/A4 T R G K I
Week
1 (5) K K D K R K T V2/A3 T4/A1 R G K I
3 (7) K K D K R K T A T R G K I
6 (11) K K8/E1/N2 D K8/N3 R K T V4/A7 T R G K I
12 (4) K K1/E1/N2 D K1/N3 R2/G2 K T4/A1 A T R3/K1 G3/E1 K I
16 (6) K5/E1 K4/N2 D K3/N3 R5/G1 K T4/I2 V3/A3 T5/A1 R3/K3 G3/E3 K I
20 (10) K9/E1 K6/E1/N1/2 D K6/N4 R9/G1 K T9/I1 V4/A6 T R7/K3 G6/E4 K I
P3 isolate
P3 (9) E N1/T8 D1/N8 N
d G N T1/I8 A T1/P8 K E K1/R8 1/V8
Region of gp120: V1 V1 V1 V2 V2 V2 C2 C2 V3 V3 C3 V5 V5
a Amino acid numbering from start of gp120 ORF, nucleotide numbering from start of aligned region.
b Sample set, number of clones sequenced shown in brackets.
c Where no subscript is shown, all clones encoded the amino acid shown, where two or more alternative codons exist, the subscript indicates the number of
clones for that codon, ‘‘ ’’ = missing codon (gap).
d Not all codons for N were the same, both AAT and AAC were detected (see Fig. 1).
Fig. 4.
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which linked the P3 sequences to the sequences from
T353 was neither significant by maximum likelihood
analysis (0.00105 F 0.002), nor was it supported by boot-
strap resampling (bootstrap value 21%, Fig. 2b). The fre-
quencies of the SF162-like and P3-like amino acids were
assessed in each of the samples obtained and, as expected, a
clear trend over time, with the accumulation of more ‘‘P3-
like’’ sequences, was seen (Table 2). However, it should be
noted that, even in the last time point analyzed (week 20), a
clone identical to the SF162 input sequence was obtained
(DNA20-9). The first P3-like signature codon detected was
a change in the V2 region, which encoded a novel glyco-
sylation site at codon 158 in 3 of 11 clones at week 6;
however, the codon involved differed from that seen in the
P3 isolate (AAT at week 6, AAC in P3 isolate, Fig. 1b and
Table 2).
The first P3-signature sequence change detected confers
neutralization escape but not increased viral infectivity
To assess whether the P3-like genetic change first
detected 6 weeks after infection of macaque T353 was the
result of adaptation to better growth in macaque cells, a G to
C change was introduced into the V2 domain of SF162 env
to generate the glycosylation site at amino acid 158
(SF162g158, g = glycan). The ability of the SF162,
SF162g158, and P3 major variant envelopes (SF162PC,
which contains the major variant sequence clone P3–2
(Hsu et al., 2003)) to mediate infection of target cells was
compared using luciferase reporter viruses. It was reasoned
that an increased rate of infection mediated by SF162g158env could translate into an enhanced replicative capacity of
the virus, which could account for the dramatic increase in
acute plasma viremia seen in the late passaged animals in
vivo (Table 1). However, in a single-round infection of
HOS.CD4 cells expressing human or rhesus macaque CCR5
with SF162, SF162g158, or SF162PC envelope pseudo-
typed reporter viruses, we found no difference between the
SF162 and SF162g158 envelopes but a large increase in
infectivity mediated by the SF162PC envelope (Fig. 4).
Thus, the genetic change at codon 158 of gp120 does not
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SF162PC envelope and hence was not selected for because
of an ability to confer such replicative advantages.
We have previously reported that addition of the g158
glycan conferred onto the virus, SHIVSF162g158, the ability to
escape from neutralization with week 20 and 66 sera from
macaque T353 (Lue et al., 2002). To assess whether this
genetic change was the result of escape from immune pre-
ssure, we measured the neutralization of SF162, SF162g158,
and SF162PC chimeric viruses with sera collected from
T353 at weeks 3 (time of seroconversion), 4, 12, 16, 20,
and 66 postinfection (Fig. 5). Neutralizing antibodies against
viruses expressing the SF162 env could be detected as early
as 3 weeks after infection, when 90% neutralization of the
virus (IC90) was achieved at a 1:40 serum dilution. These
levels increased with time, reaching IC90 titers greater than
1:1500 by week 12 which were sustained through week 20
but diminished in late stage of the disease (week 66). In
contrast, neutralizing activity against viruses expressing the
SF162g158 env was undetectable at week 3 and modest at
week 4 (IC50 of 1:80), but increased dramatically by week      
Fig. 5.12, reaching IC90 titers of 1:1280. However, by week 20
postinfection, the neutralizing titer against this variant virus
waned, giving IC90 titers of only 1:400, this titer further
decreased to 1:80 by week 66. Neutralizing antibodies
against viruses expressing the SF162PC env were only
detectable at the later stages of disease (39% neutralization
at a titer of 1:20 at week 20, IC90 of 1:40 at week 66, Fig. 5).
The dynamics of neutralizing antibody generation seen in
macaque T353 strongly supports the model of change in the
envelope sequence occurring in response to immune pres-
sure, consistent with recent reports in humans (Richman et
al., 2003; Wei et al., 2003).Discussion
In this study, we sought to elucidate the evolutionary
process underlying the increase in virulence of SHIVSF162
during serial passage. We found that HIV-1 envelope
sequences obtained even after 8 weeks of rapid in vivo
passage through rhesus macaques were indistinguishable
from the original SHIVSF162 inoculum (Fig. 2a). None of the
signature amino acids associated with the pathogenic isolate
SHIVSF162P3 recovered from passage three animal T353 at
20 weeks post-challenge was detected during the transfer
period (Fig. 1b). This consistent finding in all eight animals
leads us to conclude that in these seronegative animals, there
is no adaptive evolution of the env gene conferring im-
proved replication before seroconversion, despite the greater
than 10-fold increase in peak viremia in later passages and
the subsequent detection of a persistent elevated viral load
(set point) in two of the later passaged animals, implying the
emergence of more successfully replicating variants (Table
1). The increase in peak viremia is therefore likely to be due
to the increasing infectious dose used on sequential trans-
fers. The greater sequence diversity seen in the later pas-
saged animals (Fig. 3) may simply be the consequence of
the larger number of rounds of viral replication leading to
the genesis of more variants.
Our findings are in apparent contrast to those of Valli et
al. in which an SIVsm isolate, B670, derived from a sooty
mangabey was passaged in rhesus macaques. In those
experiments, a reduction and then an increase in polymor-
phism were seen, together with a stepwise series of changes
in the consensus sequence on each passage. As a result, a
tree-like phylogeny, consistent with a model of adaptive
evolution, was obtained (Valli and Goudsmit, 1998). It is
possible to speculate that these two sets of experiments
reflect similar processes, in which the initial inoculum
variants are expanded and turn over until an adaptive
mutation emerges, which subsequently expands to dominate
the quasispecies. With this model, the tree-like topology
obtained by Valli et al. would reflect the sequential random
removal of variants from the initial quasispecies mixture
over the first three passages (passage 1 intra-sample genetic
distance = 3.7%, passage 3 = 1.3%), followed by expansive
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variants in later passages. In the series of experiments
reported here, there is no initial polymorphism, leading us
to observe only the expansion of the quasispecies diversity
due to error accumulation.
Inspection of the sequence data obtained showed that of
all the animals, the one that succumbed to SAIDS (T353)
had the most variable quasispecies at weeks 1 and 3 (Fig. 3,
(Harouse et al., 1999; Tan et al., 1999)). No other distin-
guishing features were noted among these sequences. Sev-
eral authors (Greenier et al., 2001; Karlsson et al., 1998a;
Kimata et al., 1999; Lewis et al., 1998; Overbaugh and
Bangham, 2001; Shankarappa et al., 1998; Shpaer and
Mullins, 1993) have suggested that the diversity of the
quasispecies at initial infection may be a predictor of
subsequent progression. Our observation in macaque T353
is consistent with this. The implicit model is that the breadth
of preexisting diversity at the time of seroconversion may be
enough that, even in the face of a strong immune response,
sufficient numbers of antigenically distinct viruses are
present in the host for escape mutants to occur. The exact
value of this ‘‘diversity threshold’’ is likely to vary from
animal to animal; for T353, the average pairwise difference
of 6.5 was associated with a range of differences of up to 14
nucleotides. These maximally distinct pairs of sequences
(week 3 RNA samples RNA3–52 and RNA3–54 vs. RNA
3–61 and RNA3–62) differed at 12 of the 453 codons
sequenced (2.6%). The second highest level of diversity was
seen in animal T378, where, although the animal shows a
detectable persistent viremia, no progression has been seen
after 4 years of follow up.
Having failed to detect any of these ‘‘P3 signature amino
acids’’ in any of the samples during the passage experiment,
we next investigated serial samples from animal T353. As
expected, these samples did include several of the amino
acids detected in the P3 isolate derived from the week 20
sample; however, none of these changes was detected in any
of the 23 sequences obtained before seroconversion. This
observation, in concert with those on the other seven
animals, implies that none of the mutations which led to
the emergence of the SHIVSF162P3 pathogenic isolate oc-
curred before the seroconversion of T353, and furthermore,
that the changes seen may be the result of escape from
immune surveillance in animal T353. Indeed, the first ‘‘P3
signature amino acid’’ seen, a Lysine (K) to Asparagine (N)
substitution leading to a glycan insertion at codon 158,
occurred at week 6 (Table 2) and conferred escape from
autologous immune recognition (Fig. 5). The relative in-
ability of the sera from T353 to neutralize the virus
expressing SHIVSF162PC env is consistent with a model of
antigenic drift in which sequence changes in envelope
gp120 accumulate over time in response to immune pressure
exerted by the hosts, resulting in antigenically distinct
variants that are neutralization resistant (Cayabyab et al.,
1999; Cheng-Mayer et al., 1999; Clements et al., 1995;
Endo et al., 2000; Etemad-Moghadam et al., 1999; Greenieret al., 2001; Hsu et al., 2003; Moore et al., 2002; Ross and
Rodrigo, 2002; Si et al., 2001).
In summary, our data suggest an accumulation of random
viral changes on rapid serial passage leading to increasing
diversity and further show that it was in the animal with the
highest diversity (T353) that the mutation(s) allowing es-
cape from the neutralization response occurred, resulting in
the emergence of the pathogenic SHIVSF162P3 strain and
disease progression. Our findings are compatible with the
‘‘diversity threshold’’ theory proposed by others (Liu et al.,
1997; Lukashov et al., 1995; Nowak et al., 1991) and
highlight the importance of the selective forces exerted by
the immune response in determining the extent of diver-
gence and rate of disease progression.Materials and methods
Animal infections and specimens
All infections were carried out in juvenile rhesus mac-
aques (Macaca mulatta) housed individually at the Tulane
National Primate Research Center in compliance with its
Guide for the Care and Use of Laboratory Animals. Before
inoculation, animals were tested and found to be serologi-
cally negative for simian type D retrovirus, SIV, and simian
T-cell lymphotropic virus. The initial intravenous (i.v.)
infections were carried out with 1.4  104 50% tissue
culture infectious doses (TCID50) of the SHIVSF162 virus
clone into two macaques (P1: T373, T528) as described
previously (Harouse et al., 1999; Tan et al., 1999). Two
weeks after inoculation, 10 ml of peripheral blood and 5 ml
of bone marrow aspirate were collected from each animal,
pooled, and used to transfuse two naive monkeys (P2: T635,
T660). This inoculation schedule and protocol was per-
formed two more times in naive animal groups P3 (T353,
T833) and P4 (T378, T642). Peripheral blood and lymph
node samples were collected from each of the eight animals
over time and analyzed for plasma viremia (Bayer Diag-
nostics, Emeryville, CA), antiviral antibodies (SIA, Chiron
Corporation, Emeryville, CA (Kline et al., 1996; Thorstens-
son et al., 1991)), and changes in T cell subsets (Trucount,
Becton Dickinson, San Jose, CA).
PCR amplification, cloning, and sequencing
Genomic DNA was extracted from 5  105 PBMC and
RNA prepared from 140 Al of plasma using commercial kits
(Qiagen) and resuspended in a volume of 100 Al. A nested
PCR was used to amplify the complete gp120 region of the
envelope gene using methods similar to those previously
described (Fox et al., 1997; Hammond et al., 2001; Hayman
et al., 2001; Lewis et al., 1998; McKeating et al., 1996;
Palmer et al., 1996). Briefly, a 50-Al PCR was set up which
contained 2–5 Al of template DNA, 2.5 U of the proof-
reading ‘‘Expand’’ polymerase mixture (Roche 1 681 834,
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Mg2+), with 400 AM each of the four dNTPs, and 200 nM
each of 627L (GAT GTT GAT GAT CTG TAG TGC,
sense), 989L (TCA TCA AGT TTC TCT AYC AAA GC,
sense), 632L (GCG CCC ATA GTG CTT CCT GCT GC,
antisense), and 631L (CCA GAC TGT GAG TTG CAA
CAG ATG C, antisense). The inclusion of multiple primers
allows for PCR amplification even when one of the primers
fails to match the template sequence. The PCR consisted of
30 cycles of 92 jC for 45 s, 45 jC for 45 s, and 68 jC for
210 s and was performed in an Eppendorf thermal cycler.
For the amplification of RNA, the first round PCR was
performed using exactly the same conditions and primers
but replacing the ‘‘Expand’’ reagents with the ‘‘Titan’’ RT-
PCR system (Roche, Mannheim, cat no. 1 855 476) and
adding 40 units of RNase inhibitor (Roche) with 2–5 Al of
template RNA. These reactions were incubated for 30 min at
50 jC to allow for cDNA synthesis before commencement
of the PCR cycles. Two microliters of the completed PCR
was used to initiate a second reaction in a volume of 20 Al.
This second round of PCR mixture contained the same
reaction components as above with 200 nM of the primers
626L (GTG GGT CAC CGT CTA TTATGG G, sense) and
125Y (CAC CAC GCG TCT CTT TGC CTT GGT GGG,
antisense). The second-round PCR consisted of 25 cycles of
92 jC for 35 s, 55 jC for 35 s, and 68 jC for 150 s. Ten
microliters of the completed PCR reaction was visualized by
agarose gel electrophoresis to confirm the presence of the
PCR product and the absence of satellite bands. The clones
derived from the SHIVSF162P3 isolate were obtained in a
previous study (Hsu et al., 2003) using the primers ED5 and
ED12 (Delwart and Gordon, 1997) which amplify the V1–
V5 region of gp120. PCR products were ligated directly into
pcDNA2.1-TOPO (Invitrogen), transformed into chemically
competent rec E. coli (Stratagene, SURE), and the resul-
tant colonies screened for the presence of inserts by PCR
using two of the sequencing primers. Typically, 30–70% of
colonies were positive. Plasmid DNAwas prepared (Qiagen
miniprep kit) and the sense and antisense strands sequenced
using four primers each to give an average 2–4-fold
redundancy (Big Dye Terminator Kit, ABI). The eight
sequence chromatograms were aligned using the
Sequencher 4.1 software (Gene Codes Corp., Ann Arbor,
Mich.) and their consensus (contig) translated to give the
sequences shown here. All sequences have been deposited
with GenBank and have been given the accession numbers,
AY240970–AY241065.
Analysis of sequence diversity
The nucleotide sequences were aligned using the Clus-
talX (Thompson et al., 1994) and MacVector (Accelrys)
software packages and gaps adjusted to align to codon
boundaries using the SeAL2.0 program (A. Rambaut, Ox-
ford University, http://evolve.zoo.ox.ac.uk). Synonymous
and nonsynonymous distances were estimated using theNei and Gojorbori method implemented in PAML3.12
(Nei and Gojobori, 1986; Yang and Nielsen, 2000); maxi-
mum likelihood phylogenetic analyses were performed
using the PAUP 4.0* software package (Rogers and Swof-
ford, 1998); distance estimates were averaged using Excel
2001 (Microsoft).
Construction of envelope expression plasmids and virus
production
The construction of the envelope expression vectors
pCAGGS-SF162env and pCAGGS-SF162PCenv contain-
ing the major variant sequence clone P3–2 has been
described previously (Hsu et al., 2003). Site-directed
mutagenesis was performed using the pCAGGS-SF162env
plasmid and the complementary mutagenic oligonucleo-
tides SF162(g158)F (T TGC TCT TTC AAC GTC ACC
ACA AGC, changed codon shown in bold) and
SF162(g158)R to introduce the glycosylation site at
the base of the V2 loop (AAG-AAC, amino acid
158). The mutation in the resultant plasmid, pCAGGS-
SF162g158env, was confirmed by sequencing. To gener-
ate reporter viruses capable of a single round of replica-
tion, 293T cells were co-transfected with the envelope
expression vectors and the NL4.3-Luc-ER vector
(Connor et al., 1995) using the DMRIE-C reagent (Life
Technologies). Pseudotyped viruses were harvested at
72 h post-transfection, and p24 Gag antigen concentration
determined by enzyme-linked immunosorbent assay
(Abbott Laboratories, Abbott Park, IL). Full-length pro-
viral clones containing the envelope glycoproteins of
SF162, the SF162P3 major variant (clone P3–2, desig-
nated SF162PC), or the SF162g158 mutant were con-
structed on the genomic backbone of HIV-1 R7-3 and
viral stocks generated by transfection of 293 T cells with
proviral plasmid DNA as described previously (Lue et al.,
2002).
Infectivity and neutralization assays
For infectivity assays, HOS.CD4.CCR5 cells were plated
at 4  103 per well in 96-well plates and cultured overnight
in Dulbecco’s modified eagle’s medium (DMEM) + 10%
fetal bovine serum (FBS). The cells were pretreated with
Polybrene (2 Ag/ml) for 30 min at 37 jC and infected with
equivalent amounts (2.5 ng of p24) of each of the pseudo-
typed viruses for 3 h at 37 jC. The plates were then washed
and fresh DMEM/10% FBS added. Infectivity was quanti-
fied by detection of luciferase activity 72 h after infection
(Promega Luciferase assay performed using an MLX micro-
titer plate luminometer, Dynex Technologies, Inc., Chan-
tilly, VA). Virus neutralization was assessed using the
CEM  174 5.25 M7 reporter cell line and the chimeric
R7/3-based proviruses as described previously (Lue et al.,
2002). Briefly, serial dilutions of heat-inactivated serum
samples from macaque T353 were incubated in duplicate
P. Balfe et al. / Virology 318 (2004) 267–279278wells with equal volumes (50 Al) of each virus (2.5 ng of
p24) for 1 h at 37 jC. A total of 2  104 CEM  174
5.25M7 cells in a 100-Al volume of medium were then
added to the virus–serum mixture and cultured for 4 days
at 37 jC. Control cultures received virus incubated in the
absence of antisera. At the end of the incubation period,
cells were harvested, lysed, and luciferase activity mea-
sured. A neutralization curve was generated by plotting the
percentage of neutralization vs. serum dilution. The dilu-
tion of antiserum which resulted in a 90% inhibition (IC90)
was interpolated from this curve.Acknowledgments
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